Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma

Inclusion Criteria:

• Neck and head epidermoid carcinoma histologically proved. Patient with an ENT epidermoid tumor can be included in the study if this relapse is located in an area not irradiated yet.
• At least tumor classified T2NXM0
• Patient who can be picked up in a first surgery with a curative purpose or who must have a necessity's surgery (cervical curettage for voluminous adenopathies before radiotherapy)
• Patient without clinical or radiological sign of metastatic disease
• Good general status (OMS ≤ 2)
• Patient able to ingest food.
• Age ≥ 18 years
• Well-informed written consent, signed by the patient.
• Patient with sickness benefit

Exclusion Criteria:

• Patient with relapse ever treated by radiotherapy
• Other prospective study's participation
• Recent and massive digestive haemorrhage
• Medical contra-indication like main general status alteration, uncontrolled serious infectious disease, main uncontrolled metabolic anomaly ongoing.
• Pre-existent pulmonary pathology (BPCO, pleurisy, lymphangitis, interstitial syndrome)
• Severe cardiac pathology (stage 3 or 4 cardiac insufficiency, unstable angina pectoris, uncontrolled arrhythmia, myocardium's infarction antecedent during the year that precede the inclusion.
• Ophthalmic pathology antecedent concerning the ocular surface or lens-carrier
• Concomitant administration, by local or general tract, of drug responsible for ocular drought or which could delay the epithelial cicatrization
• Less than 1000 polynuclear neutrophil leucocytes or less than 75000 blood-platelets at inclusion
• Bilirubin at higher concentration than one point five times the normal
• Renal insufficiency (glomerular filtration flow ≤ 40 ml/min)calculated in accordance with Cockroft's formula
• Tacking of Beta blockers, amiodarone, NSAIDs, bleomycin, just before or during the study
• Pregnant or nursing women
• Patient under guardianship or trusteeship.